Brief
AstraZeneca invests $2bn in Summit Therapeutics to advance cancer drug
The London‑listed pharma giant has committed £1.5bn to the US company, aiming to combine Summit’s experimental therapy with AstraZeneca’s portfolio, including Sone‑Ve.
By Felo News Desk · Published
AstraZeneca announced a £1.5 billion equity investment in US‑based Summit Therapeutics, a move designed to accelerate the development of Summit’s experimental cancer drug, ivonescimab, and to explore combination trials with AstraZeneca’s antibody drug conjugates portfolio, including sonesitatug vedotin (Sone‑Ve). The deal was disclosed on 29 September 2026 and was reported by both the London Evening Standard and The Independent.
Investment details
The investment, valued at two billion US dollars, will allow the two companies to share the costs and expertise required to bring ivonescimab to market. Both parties will retain development and commercial rights to their respective medicines under the agreement, and will jointly contribute to trial costs.
Strategic focus
Summit’s ivonescimab targets specific proteins on cancer cells to stop their growth, while AstraZeneca’s Sone‑Ve is an antibody drug conjugate already in trials for gastrointestinal cancer. Susan Galbraith, AstraZeneca’s executive vice‑president, said the partnership could "enable new regimens that raise the bar for patients with cancer across the treatment landscape." Dr Maky Zanganeh, president and co‑chief executive of Summit, added that the collaboration "opens an exciting new chapter in the advancement of ivonescimab."
Market reaction
Following the announcement, Summit’s shares rose by nearly 20% after New York markets closed, while AstraZeneca’s shares were up 2% in London the following morning.
Key facts
- AstraZeneca invested £1.5bn ($2bn) in Summit Therapeutics (standard.co.uk)
- The investment aims to accelerate development of Summit’s ivonescimab (standard.co.uk)
- Both companies will retain development and commercial rights to their respective medicines (standard.co.uk)
- Summit’s shares rose nearly 20% after the announcement (standard.co.uk)
- AstraZeneca’s shares were up 2% in London the next day (standard.co.uk)
Background
None
Why it matters
The partnership could speed the availability of a new cancer therapy and expand AstraZeneca’s antibody drug conjugate portfolio.
What happens next
Trials combining ivonescimab with Sone‑Ve are expected to begin imminently, according to the companies’ statements.
Sources
- [1] standard.co.uk
- [2] independent.co.uk
